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Conversion of human 5-lipoxygenase to a
15-lipoxygenase by a point mutation to mimic
phosphorylation at Serine-663
Nathaniel C. Gilbert,* Zhe Rui,* David B. Neau,† Maria T. Waight,* Sue G. Bartlett,*
William E. Boeglin,‡,§ Alan R. Brash,‡,§ and Marcia E. Newcomer*,1
*Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana, USA; †Northeastern
Collaborative Access Team, Argonne National Laboratory, Argonne, Illinois, USA; and ‡Department of
Pharmacology and §Vanderbilt Institute for Chemical Biology, Vanderbilt University, Nashville, Tennessee
ABSTRACT The enzyme 5-lipoxygenase (5-LOX) initi-
ates biosynthesis of the proinflammatory leukotriene lipid
mediators and, together with 15-LOX, is also required for
synthesis of the anti-inflammatory lipoxins. The catalytic
activity of 5-LOX is regulated through multiple mecha-
nisms, including Ca2-targeted membrane binding and
phosphorylation at specific serine residues. To investigate
the consequences of phosphorylation at S663, we mutated
the residue to the phosphorylation mimic Asp, providing
a homogenous preparation suitable for catalytic and struc-
tural studies. The S663D enzyme exhibits robust 15-LOX
activity, as determined by spectrophotometric and HPLC
analyses, with only traces of 5-LOX activity remaining;
synthesis of the anti-inflammatory lipoxin A4 from arachi-
donic acid is also detected. The crystal structure of the
S663D mutant in the absence and presence of arachidonic
acid (in the context of the previously reported Stable-5-
LOX) reveals substantial remodeling of helices that de-
fine the active site so that the once fully encapsulated
catalytic machinery is solvent accessible. Our results sug-
gest that phosphorylation of 5-LOX at S663 could not only
down-regulate leukotriene synthesis but also stimulate
lipoxin production in inflammatory cells that do not
express 15-LOX, thus redirecting lipid mediator biosyn-
thesis to the production of proresolving mediators of
inflammation.—Gilbert, N. C., Rui, Z., Neau, D. B.,
Waight, M. T., Bartlett, S. G., Boeglin, W. E., Brash, A. R.,
Newcomer, M. E. Conversion of human 5-lipoxygenase to
a 15-lipoxygenase by a point mutation to mimic phosphor-
ylation at Serine-663. FASEB J. 26, 3222–3229 (2012).
www.fasebj.org
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Leukotrienes (LTs) are potent mediators of the inflam-
matory response derived from arachidonic acid (AA). On
leukocyte activation, AA is released from the nuclear
membrane by the action of cytosolic phospholipase A2
and binds 5-lipoxygenase-activating protein (FLAP). The
increased Ca2 concentration of the activated cells simul-
taneously promotes translocation of 5-lipoxygenase (5-
LOX) to the nuclear membrane, where it acquires its
substrate from FLAP (1, 2). AA is converted to leukotriene
A4 (LTA4) in a 2-step reaction that produces the 5S-
isomer of hydroperoxyeicosatetraenoic acid (5S-HPETE)
as an intermediate (3, 4). While 5-LOX production of
LTA4 promotes inflammation, 5-LOX is also required for
the synthesis of the lipoxins (LXs) (5, 6), structurally
related compounds with anti-inflammatory properties
that promote resolution of inflammation. LXs are the
products of successive LOX reactions. For example LXA4
is synthesized by the actions of both 15-LOX and 5-LOX.
15-LOX generates 15S-HPETE, which serves as a substrate
for 5-LOX; 5-LOX converts the 15-LOX product to LXA4.
15-LOX and 5-LOX are generally not present in the same
cell types and LX synthesis has been reported to be
transcellular (7–10).
LT production is regulated by phosphorylation of
5-LOX, and 3 kinase-targeted sites have been reported:
Ser-271, Ser-523, and Ser-663 (11–15). S663 has been
shown to be a substrate for ERK2 in vitro (11–13, 16),
and its phosphorylation is thought to lead to increased
enzyme activity (12). Paradoxically, 5-LOX product
formation has been observed to be depressed in cells in
which ERK2 activity is up-regulated (17). To under-
stand the structural basis for altered LT production as
a consequence of phosphorylation at S663, we pre-
pared the S663D mutant of 5-LOX to mimic the
phosphorylated state. The mutation of a Ser to an Asp
is a well-established method to approximate the phos-
phorylated form of an enzyme for studies that require a
homogenous sample of the modified enzyme (18). The
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mutation was made in the context of Stable-5-LOX, a
soluble 5-LOX that lacks putative membrane insertion
residues and retains wild-type activity (19). The crystal
structure of the S663D-Stable-5-LOX was determined in
the absence and presence of substrate. The crystal
structure of the enzyme with AA, combined with both
altered substrate and product profiles for the modified
enzyme, lead us to suggest that phosphorylation of
5-LOX at S663 converts the enzyme to a robust 15-LOX.
Moreover, the same mutation in the context of the wild-
type enzyme also results in 15-LOX activity. Our data
suggest that the phosphorylation of 5-LOX at S663 can
both down-regulate production of proinflammatory
LTs and stimulate production of antiinflammatory LXs
in cells which do not express 15-LOX.
MATERIALS AND METHODS
Construction of plasmid for protein expression
The 5-LOX insert in pCR2.1 was amplified by the polymerase
chain reaction, cloned into pET28b (Novagen, San Diego,
CA, USA), and then subcloned into pET14b for leaky expres-
sion. Mutations were constructed using whole-plasmid PCR
(20). Primers were constructed to contain silent mutations
that facilitated screening of plasmids. Small-scale expression
to assess expression levels and solubility of the various mutant
5-LOXs was carried out by autoinduction (21).
Protein expression and purification
Protein was expressed and purified as described previously
for Stable 5-LOX (19). Purification of the wild-type enzyme
harboring the S663D mutation required 0.5% dodecyl malto-
side in the lysis buffer. Assays for product specificity for that
enzyme were preformed with the protein that eluted from the
Ni-NTA column. No detergent was used for either the Stable-
5-LOX S663D or S663A mutant purifications, or that of the
parent enzyme.
Enzyme assays
Stable-5-LOX and its S663D mutant were assayed by monitor-
ing the increase in absorbance at 238 nm in an Agilent 8453
Diode Array Spectrophotometer (Agilent Technologies,
Santa Clara, CA, USA). The different substrates AA, dihomo-
-linolenic acid (DGLA), and N-arachidonyl glycine (NAGly)
were diluted to 10 mM in 100% ethanol or dimethyl sulfox-
ide. Assays were performed in 20 mM Tris-HCl (pH 7.5) and
150 mM NaCl with 140 nM enzyme. The concentration of
substrates was varied from 1.5 to 30 M for the determination
of kinetic parameters.
The products of the reaction mixtures were identified from
incubations as described previously (19). Briefly, the reaction
was initiated by addition of AA (10–100 M) added in 1–5 l
ethanol and monitored by UV spectroscopy until completion.
Products were extracted by adjusting the solution to pH 4
by addition of 50 l 1 M KH2PO4 plus 5 l 1N HCl and
vigorous mixing with 2 vol of dichloromethane. After a brief
centrifugation to clear the phases, the lower organic layer was
collected, washed twice with 0.5 ml water, taken to dryness
under a stream of nitrogen, and then dissolved in a small
volume of methanol for storage at 20°C. Prior to HPLC,
peroxides were reduced by the addition of triphenylphos-
phine. Thus, the elution times are for the hydroxyproducts
(HETEs), rather than the HPETEs. Reversed-phase HPLC was
performed using Agilent 1100 series equipment with a Waters
C18 Symmetry column (250.46 cm; Waters Corp., Milford,
MA, USA) or a Dionex HPLC with a diode array detector
(Dionex, Sunnyvale, CA, USA) and a Discovery HS C18
column. The mobile phase was acetonitrile/water/formic
acid (60:40:0.01, v/v/v) or methanol/water/glacial acetic
acid (80:20:0.01, v/v/v). The chirality of the product was
confirmed as 5S or 15S by chromatography on a Chiralpak AD
column (4.6250 mm; Chiral Technologies, Inc., West Ches-
ter, PA, USA) with a mobile phase of hexane/methanol
(100:2) at a flow rate of 1 ml/min. The HETEs were con-
verted to the methyl esters before chiral analysis using ethe-
real diazomethane.
LX assays
The products of the coincubation of S663D-Stable-5-LOX and
Stable-5-LOX were extracted as above and separated by
reverse-phase HPLC. The mobile phase varied from acetoni-
trile/water/formic acid at 20:80:0.01 to 60:40:0.01 over 20 ml.
Enzymes (at 1 M) were incubated with 70 M AA for 10 min
at 22°C in a volume of 700 l. Extraction was performed after
a second addition of fresh enzyme and an additional 10-min
incubation period.
Crystallization
Stable-5-LOX S663D and Stable-5-LOX S663A crystals were
grown by hanging-drop vapor diffusion at 295 K by mixing 1
l protein (8 mg/ml) and 2 l reservoir solution containing
8–10% Tacsimate, pH 6.0 (Hampton Research, Aliso Viejo,
CA, USA). Crystals were also grown in an anaerobic chamber
from Coy Laboratories (Grass Lake, MI, USA), and then
soaked in 70% Tacsimate (pH 6.0) with 1 mg/ml AA for 3 h.
Crystals were frozen in liquid nitrogen, if applicable inside an
anaerobic chamber, for shipment and data collection.
Structure determination
Diffraction data were collected at 100 K at the NE-CAT
beamline 24-ID-E at the Advanced Photon Source (Ar-
gonne, IL, USA). Data were processed with Xia2 (22). A
monomer (unrestrained by noncrystallographic symmetry
and stripped of water molecules) of the previously solved
Stable-5-LOX structure (2.4 Å resolution), was used to
position both chains in the asymmetric unit with Phaser
(23). The molecular replacement solution was refined in
Phenix to 2.1 Å (24). Clear density for the forked side
chain of the S663D mutant (in the absence of substrate), as
well as for the new position for D655, was evident in the
Fo-Fc electron density map. In contrast, significant regions
of the search model did not have main chain density in the
2Fo-Fc electron density map calculated with data collected
with AA-S663D crystals. These regions of the model were
deleted, and the model was rebuilt over several cycles of
manual rebuilding and refinement. Manual model build-
ing was performed with Coot (25). Further refinement in
Phenix (24) was performed with individual atomic dis-
placement factors (B factors) and automatic water picking.
Illustrations were prepared with PyMOL (26). The PDB
codes are 3V92, 3V98, 3V99 for the S663A, S663D, and
S663D plus AA structures, respectively.
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RESULTS
Catalytic activity of the Ser-663Asp mutant of human
5-LOX
S663D and S663A mutations in Stable-5-LOX were
overexpressed in E. coli and purified as previously
reported for Stable-5-LOX (19). Stable 5-LOX has been
shown to a have Km for substrate equivalent to the
wild-type enzyme. When the production of HPETE by
the S663D mutant was monitored by the absorbance at
238 nm, the rate of reaction was triple that of its parent
enzyme, while the affinity for substrate (indicated by
Km) was enhanced (Table 1). HPLC analysis of the
reaction products revealed that the S663D mutant
produced 15-HPETE (Fig. 1), with 0 to at most 10%
5-HPETE in different incubations. Chiral HPLC analysis
indicated that the product is exclusively the 15S enantio-
mer (data not shown). The S663D mutation in the
context of the wild-type 5-LOX protein was also prepared
and incubated with AA, and the products were analyzed
by HPLC; the results of the analysis established that
S663D-5-LOX also produces 15-HPETE. By contrast, the
S663A mutant enzyme exhibits wild-type catalytic activity,
forming 5-HPETE as the sole product; the maximal rate
of reaction of the S663A mutant is similar to that of
Stable-5-LOX, although the Km for substrate is signifi-
cantly higher (Table 1). It is difficult to make a direct
comparison of the turnover numbers of the wild-type vs.
Stable-5-LOX, as the latter enzyme has been engineered
to have a longer half-life. Thus, as expected, the turnover
rate for Stable-5-LOX is 10-fold improved over that for
the fully activated wild-type enzyme (27).
Distinct differences exist in the fatty acid substrate
specificities for 5-LOX and 15-LOX enzymes. While AA
is the prototypic substrate for either isoform, 5-LOX is
almost unreactive with linoleic acid, DGLA, or arachid-
onate derivatives bearing a bulky carboxyl ester or
amide (28, 29), all of which are acceptable substrates
for 15-LOX. Thus, it was of interest to examine the
activity of the S663D mutant enzyme with these poor
5-LOX substrates. The results indicate that the S663D
mutant efficiently oxygenated linoleic acid, DGLA, and
NAGly at rates approximately equivalent to that for AA
(Table 1). The products were identified after reduction
of the hydroperoxides as 13S-hydroxylinoleate (only
1% 9-hydroxy), 15-hydroxy-DGLA, and the 15-hydroxy-
N-Gly-20:4, respectively (data not shown). Thus, both of
the eicosanoid substrates are accommodated in the
active site so that C15, and not C5, is positioned to
accept the peroxide group. S663D-Stable-5-LOX dis-
plays a robust catalytic activity with all of the typical
15-LOX substrates. Under the same conditions, Stable-
5-LOX or its S663A mutant did not transform linoleic
acid, DGLA, or NAGly at appreciable rates.
The potential for LX biosynthesis via modification at
Ser-663
Biosynthesis of the anti-inflammatory LX mediators
(e.g., LXA, 5,6,15-trihydroxyeicosatetraenoic acid) is
considered to involve the actions of multiple cell
types and multiple LOX enzymes, hence the deriva-
tion of the name lipoxin from “lipoxygenase interac-
tion” products. Our discovery of a means whereby a
cellular 5-LOX might be transformed into a func-
tional 15-LOX (potentially by phosphorylation at
S663) opens the door to the production of LXs by
5-LOX and modified 5-LOX within a single cell. To
mimic this possibility in vitro; i.e., to see whether
5-LOX and its S663D mutant could synthesize LXs in
the absence of a native 15-LOX, Stable-5-LOX and its
S663D mutant were incubated together with AA.
HPLC analysis of the products of the coincubation
revealed a compound with elution time and UV
spectra characteristic of a LXA4 standard, formed
together with other LX isomers (Fig. 2).
Crystallization of the stable-5-LOX mutant enzymes
To gain insights into the structural basis for the striking
effects of the S663D mutation, the S663D and S663A
proteins were crystallized in an anaerobic chamber
under conditions described for Stable-5-LOX (19). The
strict anaerobic conditions allowed exposure of the
crystals to AA without inducing its transformation to
product. In this way we could determine the crystal
structures of the S663D mutant enzyme in the presence
(2.25 Å) and absence (2.1 Å) of AA. In addition, the
structure of the S663A protein was determined at 2.74
TABLE 1. Kinetic parameters for Stable-5-LOX and its S663A
and S663D mutants
Enzyme Substrate Km (M) kcat (s
1)
Stable-5-LOX AA 11  0.02 0.30  0.02
DGLA ND ND
NAGly ND ND
S663A-Stable-5-LOX AA 42  11 0.43  0.06
DGLA ND ND
NAGly ND ND
S663D-Stable-5-LOX AA 3.2  0.3 0.85  0.03
DGLA 1.2  0.2 0.42  0.02
NAGly 1.6  0.6 0.51  0.07
Values are presented as means  sd. ND, not determined.
Figure 1. Product identification for S663D-Stable5-LOX.
HPLC trace of the triphenylphosphine reduced product of
AA oxidation by the S663D mutant of Stable-5-LOX.
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Å resolution. The data and refinement statistics are
given in Table 2.
Structures of the S663 mutant enzymes in the absence
of AA
Significantly, in the absence of AA, the structures of
both the S663D and S663A mutants are essentially
unchanged from that of the parent enzyme Stable-5-
LOX (rmsd 0.22 and 0.25 Å, respectively, Fig. 3A, B).
So, in the absence of substrate, the mutations have little
effect on the overall structure. The structures display
the general features typical of all LOXs, the N-terminal
-barrel domain, which in 5-LOX harbors the Ca2 ions
that promote membrane binding, and a larger 	-helical
domain where the catalytic iron resides (30–35). S663
is located 10 residues upstream of the C-terminal Ile
that tucks into the catalytic domain helical bundle so
that the free main-chain carboxyl can complete the
iron coordination sphere characteristic of all LOXs.
The elongated active site is sheltered by an arched helix
and in Stable-5-LOX is “corked” at one end by the side
chains of F177 and Y181. The opposite end is sealed by
W147. Consequently, the active site cavity is not acces-
sible to bulk solvent, and it is not obvious how substrate
gains access to the catalytic machinery of 5-LOX.
Structure of the S663D mutant in the presence of AA
The structure obtained from crystals of S663D-Stable-5-
LOX soaked in AA under anaerobic conditions revealed a
difference in electron density attributable to AA in one of
the monomers in the asymmetric unit (Fig. 3C, D) and
dramatic AA-induced conformational changes in both
monomers (Fig. 4 and Supplemental Fig. S1). When the
Stable-5-LOX structure is superimposed on that for the
S663D mutant in the presence of AA, a total of 40 amino
acids have no counterparts, and the RMSD for the re-
maining 630 is 0.46 Å (Fig. 4A). Four short polypeptide
segments that are normally visible in the electron density
map show no electron density in the AA-soaked crystal.
These segments begin at amino acids 173, 189, 414, and
610 and include 4 amino acids that cover the active site
(Fig. 4). The peptide that contains W605 and F610 (Fig. 4B)
occupies a central position between the site of phosphoryla-
tion at 663 and the disordered peptides that define the active
site in the apo structure. This region appears to be the
communication hub that transduces a conformational
change from S663 to the active site region.
The result of the remodeling in the AA-soaked crystal
of S663D is a conspicuously accessible catalytic iron
(Fig. 4D). The remodeling includes the reorientation
of helical segments and disordering of extensive non-
helical and helical regions and results in an exposed
active site, an open conformation. Two helices that
normally help define the active sites of LOXs are
helix-	2, which in 5-LOX is shorter and segmented
relative to this element in other LOX structures, and an
“arched” helix that contains a reverse turn insertion so
that it curves away from the helical bundle to shelter an
access channel to the catalytic iron (Fig. 4A, D). Both
the segmented 	2 and the arched helix undergo exten-
sive remodeling in the presence of substrate. The loop
(aa 171–176) that precedes the first segment of 	2 is no
longer visible in the electron density map, and the
segment of helix itself is both shortened by three amino
acids and slightly shifted. The next segment of 	2 (aa
190–194) and the following 3-turn helix (aa 204–215)
are fully displaced from their positions in the AA-free
structure. Moreover, an extensive portion of the arched
helix (from Leu-415 at the apex of the arch to its C
terminus at 428) is not visible (Fig. 4C). The overall
changes are summarized in Supplemental Fig S1.
Location of AA in the S663D crystal structure
As mentioned above, difference Fourier electron density
(at 3 sd above the mean) attributable to a portion of AA
is visible in one of the monomers of the asymmetric unit.
(Both monomers display the conformational change de-
scribed above.) A curved density, centered above the
catalytic iron, that can encompass 16 carbons of the
substrate appears poised for attack (Fig. 3C and Supple-
mental Fig. S2). The partial density permits positioning of
the substrate, but given that the AA is not restrained at
either end by protein-substrate contacts (Fig. 3D), it is not
possible to unambiguously determine its orientation in
Figure 2. Coincubation of Stable-5-LOX and its S663D muta-
tion with AA yields LXA4. Top panel: elution profile for LXA4
standard. Bottom panel: reversed-phase HPLC chromato-
gram of the analysis of the incubation mixture. LXA4 is clearly
distinguishable in the mixture of tri-HETE peaks observed by
its retention time (23.85 min) and UV spectrum (inset); the
nearby chromatographic peaks exhibit a similar UV chro-
mophore and are LX stereoisomers.
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the cavity. In Fig. 3D and Supplemental Fig. S2, the AA is
positioned for attack at C13 to generate the 15S-HPETE,
in agreement with the HPLC data.
DISCUSSION
S663 modification and LOX activity
Our results establish that the S663D mutation in human
5-LOX, with introduction of the Asp residue designed to
mimic S663 phosphorylation (36, 37), results in a dra-
matic change in the specificity of oxygenation from purely
5S to almost purely 15S. It remains to be investigated how
this relates to the actual phosphorylation of 5-LOX at
S663, yet we can offer some arguments that support our
interpretation that our results mimic a biologically rele-
vant post-translational modification event. Paradoxically,
a review of the literature on 5-LOX phosphorylation
shows that generally it is inferred that 5-LOX phosphory-
lation at S663 is associated with enzyme activation; i.e., the
opposite of what our finding predicts. This inference is
based on experiments in which the priming and subse-
quent stimulation of cells is associated with increased
ERK1/2 activation, increased 5-LOX phosphorylation
(that can be eliminated using the S663A enzyme, imply-
ing that it occurs at S663, and is blocked by ERK1/2
inhibitors), and, most strikingly, increased LT product
formation. Although at first glance these observations
support an activation role for phosphorylation at S663,
some caveats are in order. Several parameters are altered
when the cells are primed and stimulated. One is the
phosphorylation, the extent of which is unknown, yet is
quite likely to be low, perhaps only a few percent (38).
Significant other factors are the increased supply of
substrate (increased release of AA) and the enhanced
5-LOX translocation (16, 17, 39), both of which are
optimized through cell priming and kinase activation, and
both of which will increase product synthesis. Thus, while
an associated 15-LOX activity has not been reported,
these experiments were designed to measure the effect of
5-LOX phosphorylation on 5-LOX product formation in
cells. They do not rule out the possibility of a subpopula-
tion of 5-LOX that manifests a 15-LOX activity.
The crystal structures show that the S663D and
S663A mutations have no effect on the overall protein
fold, and the structures are almost indistinguishable
from the parent Stable-5-LOX. Linoleic acid, DGLA,









Space group P21 P21 P21
Cell dimensions
a, b, c (Å) 55.41, 202.50, 76.97 51.75, 200.84, 72.18 55.19, 202.38, 76.99
	,, (deg) 90.00, 109.82, 90.00 90.00, 105.65, 90.00 90.00, 109.91, 90.00
Wavelength 0.97915 0.97915 0.979180
Resolution (Å) 49.38–2.07 (2.12–2.07) 35.57–2.25 49.35–2.74 (2.80–2.74)
Rp.i.m. 0.079 (0.345) 0.069 (0.350) 0.205 (0.370)
Rmerge 0.114 (0.482) 0.077 (0.385) 0.267 (0.524)
I/
I 6.0 (2.0) 9.8 (2.7) 5.9 (2.0)
Completeness (%) 99.8 (99.0) 94.3 (73.3) 98.9 (96.2)
Redundancy 3.6 (3.0) 2.9 (1.6) 3.3 (2.8)
Refinement
Resolution (Å) 41.49–2.07 (2.12–2.07) 35.58–2.25 (2.31–2.25) 41.47–2.74 (2.80–2.74)
Reflections 91,112 (1983) 62,613 (2000) 41,033 (2061)
Rwork/Rfree 16.64/19.67 (22.66/25.63) 18.65/23.30 (23.49/31.75) 18.29/23.84 (29.23/34.44)
Atoms
Protein 10,960 10,352 10,930
Water 956 392 161
Fe 2 2 2
B factors (Å2)
Protein 25.83 33.32 40.55
AA 74.37 32.97
Fe 11.90 17.61
Water 29.62 36.83 27.14
Deviations (rms)
Bond lengths (Å) 0.002 0.003 0.003
Bond angles (deg) 0.691 0.661 0.669
Ramachandrana
Outliers (%) 0.0 0.1 0.0
Favored (%) 97.8 97.9 98.1
Values in parentheses are for the highest resolution shell; Rp.i.m.  h [1/(nh  1)] l Ihl  Ih/h lIh; Rmerge  h i |Ii  Ih|/h i I;
Rwork   Fo|  |Fc/ |Fo|, where Fo and Fc are the observed and calculated structure factor amplitudes, respectively. Rfree was calculated using
3.2% of the total reflections. aRemaining residues lie in allowed regions.
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and NAGly are poor substrates for 5-LOX but are
readily oxygenated at the 6 carbon (C15) by S663D-
Stable-5-LOX. Linoleate and DGLA lack a pentadiene
centered at C7 (which must align at the catalytic iron
for attack for the production of 5-HPETE), and NAGly
carries a bulky group at the carboxyl. None of these
analogs are suitable 5-LOX substrates. The activity of
the S663D mutant with these substrates, however, is
consistent both with their identical structure to AA at
the  end of the carbon chain, as well as the predicted
tail-first binding associated with 15-LOX activity (29).
The implication of the tail-first binding is that the
structural differences at the carboxyl end of the carbon
chain have little effect on catalysis in the active site.
AA bound in the S663D enzyme
The structure determined with data obtained from
crystals of the phosphorylation mimic S663D-Stable-5-
LOX soaked in AA under anaerobic conditions re-
Figure 3. Comparison of the structures of Sta-
ble-5-LOX (gray) and the S663D mutant (blue).
A) Cartoon rendering of the enzymes in the
absence of substrate. Box indicates the region
amplified in panel B. B) Detail at mutation: the
negative charge of S663D results in a reorienta-
tion of D665. C) Difference density (at 3
)
apparent in the Fo-Fc map after molecular re-
placement and deletion of peptide regions
where there is no electron density. Bulge ema-
nating from the Fe is likely due to a water
molecule positioned in the Fe coordination
sphere for attack on the substrate. The long
continuous density, with some broken pieces
fthat complement it to reveal a U-shape, was
interpreted as AA. D) AA as modeled in the
refined structure. Amino acid side chains within
5 Å of the substrate are included.
Figure 4. AA-induced remodeling (red) of the
S663D phosphorylation mimic of Stable-5-LOX
(blue; with the arched helix highlighted with
dark blue coloring, and helix 	2 in light blue).
A) Stable-5-LOX C	 trace with cartoon render-
ing in the regions of remodeling. Shifts in
helical placement as well as helix-to-disorder
transitions are introduced across an extensive
region of the protein. Arched helix is in dark
blue; 	2 (which is segmented) in light blue.
Carboxyl group of the C terminus can be seen
in the Fe (orange) coordination sphere. S663D
is in green spheres, on the back side of the
protein. B) Contact network of the S663D mu-
tant of Stable-5-LOX (blue, sphere/stick ren-
dering) that connects the site of phosphoryla-
tion (green) to the FY “cork” (Y181) that plugs
the active site. View is from the back side of the
protein as depicted in panel A. Arrow indicates
the direction of rotation relative to A. Both
F610 and W605 are positioned to play a role in
transduction of the conformational changes.
C-terminal Ile (I673; stick rendering) and the
peptide backbone (gray cartoon) leading from
S663 are in gray. Remodeled helical regions are
depicted in cartoon rendering, colored as in
panel A. Key remodeled residues are depicted in red sphere/stick rendering. In the presence of AA, Y181 can be seen popped
open. C) Remodeled helices, rotated (arrow indicates direction of rotation relative to B) and viewed from above. Extent of
AA-induced remodeling is significant in the area that defines the active site. Note the difference in position of Q198. Helical
coloring as in panel A. D) Contours of the active site cavity are rendered as a white surface. Superimposed on the surface
rendering is a stick rendering of the S663D mutant in the absence of AA. Note that the arched helix (dark blue), together with
elements of 	2 (light blue), covers this cavity and obstructs access.
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vealed a dramatic substrate-induced conformational
change. In this discussion, we refer to the “substrate-
induced changes” in enzyme structure because AA is
visible in one monomer of the asymmetric unit, yet
both monomers exhibit structural alterations. The
active site, which is completely inaccessible in the apo
structures of Stable-5-LOX and its apo-S663A and
S663D mutants, appears blown open; the highly
conserved arched helix, present in all full-length LOX
structures determined to date, is not visible in the
electron density maps. The result is an unprotected
catalytic site readily accessible to AA, and its analogs
DGLA and NAGly.
Relation of structure to the altered catalysis
5-LOX produces 5S-HPETE, and the stereochemistry is
consistent with the carboxyl end of the substrate lying
at the end of the active site cavity closed by W147
(head-first rather than tail-first). The 15S product of
the S663D is consistent with the inverse orientation,
with the carboxylate at the FY cork end of the cavity
(shown in Fig. 3D and Supplemental Fig. S2). There-
fore, a simple reversal of substrate orientation in the
cavity is all that is required to convert a 5-S-LOX to a
15-S-LOX; such an inversion is consistent with the
product stereochemistry of S663D-Stable-5-LOX and
LOX regiospecificity. Inversion of AA places C13 in the
location of C7 to change the positional specificity of
the enzyme and the stereochemistry of the product.
The robust 15-LOX activity is supported by the im-
proved kinetic parameters for the S663D mutant, and
the distinctly open, and readily accessible, active site as
a result of the substrate- induced conformational
change described. Moreover, it is noteworthy that the
highest turnover rates in the literature among LOXs are
for the 15-LOX isoforms, as well as other LOXs predicted
to bind substrate tail-first like 8R-LOX (40–42).
Detailed considerations of the structural changes
In the structure of Stable-5-LOX, S663 is at the amino
terminus of a 310 helix, and the side-chain -OH partic-
ipates in an H-bond with the side chain of D665. With
the addition of the negative charge at S663, D665 is
nudged toward R666, which is in van der Waals contact
with F610. In the presence of AA, the loop that contains
F610 is not visible, and the helix that is just 2 residues
upstream, the penultimate helix of the catalytic do-
main, is slightly shifted so that W605 bumps the first
segment of the active-site-defining helix 	2. As a con-
sequence, the 	2 segment is shifted relative to its
position in the Stable-5-LOX (and the S663D- and
S663A-mutant structures in the absence of AA). In
addition, the arched helix is freed of the restraints that
tether the C-terminal end by both repositioning of
helices and order-to-disorder transitions in the vicinity.
In effect, a network of H bonds and van der Waals
contacts is disrupted by the presence of the negative
charge, and this disruption impacts the locations of
both 	2 and the arched helix (Fig. 4B–D). Because it
shelters the large catalytic site, the arched helix has
limited contact within the catalytic domain; it is not
adequately restrained to remain in position and enclose
the active site.
The paucity of stabilizing contacts between the
arched helix and the remainder of the catalytic domain
was vividly illustrated by a structure of a truncated
12-LOX lacking the C2-domain (3D3L): neither 	2 or
the arched helix are positioned as they are in the
full-length structures. The fragile nature of the intra-
molecular contacts between this active-site-defining he-
lix results in a 5-LOX poised for a striking conforma-
tional change by the introduction of a negative charge
distal to the active site. It appears that the introduc-
tion of a negative charge at position 663 allows
substrate to trigger a large conformational change to
expose an active site cavity and allow for its alternate
positioning.
The potential for 5-LOX mediated LX biosynthesis
and anti-inflammatory activity
We demonstrated here that LXA4 is produced from
coincubation of Stable-5-LOX and its S663D mutant.
This result illustrates the possibility of the biosynthesis
of LXs within a 5-LOX expressing cell in which native
and modified enzyme might cooperate in the produc-
tion of these trihydroxy anti-inflammatory mediators.
Questions about the efficiency of such a system can be
considered in comparison to the alternatives, including
the current concept that cell-to-cell transfer of an
intermediate is one of the pathways in the production
of LXs. Notably, it was shown recently that depletion of
eosinophils from mouse leukocytes, while abrogating
12/15-LOX activity, still allowed for significant produc-
tion of both 15-HETE and LXA4 (43). Our finding that
Stable-5-LOX can be converted to a 15-LOX might
explain this observation.
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